Containing the Cost of Heart Failure Management: A Focus on Reducing Readmissions

Heart Failure Clinics

Volumn 13, Issue 1, 2017, Pages 21-28

  Soundarraj, Dwarakraj ^a   Singh, Vini ^b   Satija, Vaibhav ^b   Thakur, Ranjan K ^b  

^a Liberty Hospital   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Cost; Heart failure; Readmissions

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CARDIAC RESYNCHRONIZATION THERAPY; COST; DIASTOLIC HEART FAILURE; DISEASE EXACERBATION; EMERGENCY WARD; EVIDENCE BASED PRACTICE; EXERCISE; HEALTH CENTER; HEART FAILURE; HEART REHABILITATION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); OBSERVATION UNIT; OUTPATIENT INFUSION CENTER; PALLIATIVE THERAPY; PREDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSITIONAL CARE; COST CONTROL; DISEASE MANAGEMENT; ECONOMICS; HEALTH CARE COST; INCIDENCE; MEDICAID; MEDICARE; PREVALENCE; PROCEDURES; SOCIOECONOMICS; STANDARDS; UNITED STATES;

COST SAVINGS; DISEASE MANAGEMENT; HEALTH CARE COSTS; HEART FAILURE; HOSPITALIZATION; HUMANS; INCIDENCE; MEDICAID; MEDICARE; PATIENT READMISSION; PREVALENCE; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84996743331     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2016.07.002     Document Type: Review

References (52)

1. 1 Available at: http://www.cdc.gov/nchs/data/hus/hus13.pdf#112. Accessed January 11, 2015.
2. 2 Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb160.jsp. Accessed January 11, 2015.
3. 3 Heidenreich, P.A., Albert, N.M., Allen, L.A., et al., American Heart Association Advocacy Coordinating Committee, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Stroke Council, Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6:3 (2013), 606–619.
4. 4 Anderson, G.F., Steinberg, E.P., Hospital readmissions in the Medicare population. N Engl J Med 311:21 (1984), 1349–1353.
5. 5 Jencks, S.F., Williams, M.V., Coleman, E.A., Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 360:14 (2009), 1418–1428.
6. 6 Bueno, H., Ross, J.S., Wang, Y., et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA 303:21 (2010), 2141–2147.
7. 7 Epstein, A.M., Jha, A.K., Orav, E.J., The relationship between hospital admission rates and rehospitalizations. N Engl J Med 365:24 (2011), 2287–2295.
8. 8 Joynt, K.E., Orav, E.J., Jha, A.K., Thirty-day readmission rates for Medicare beneficiaries by race and site of care. JAMA 305:7 (2011), 675–681.
9. 9 Joynt, K.E., Jha, A.K., Who has higher readmission rates for heart failure, and why? Implications for efforts to improve care using financial incentives. Circ Cardiovasc Qual Outcomes 4:1 (2011), 53–59.
10. 10 Kansagara, D., Englander, H., Salanitro, A., et al. Risk prediction models for hospital readmission: a systematic review. JAMA 306:15 (2011), 1688–1698.
11. 11 Hernandez, A.F., Greiner, M.A., Fonarow, G.C., et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA 303:17 (2010), 1716–1722.
12. 12 Peikes, D., Chen, A., Schore, J., et al. Effects of care coordination on hospitalization, quality of care, and health care expenditures among Medicare beneficiaries: 15 randomized trials. JAMA 301:6 (2009), 603–618.
13. 13 Rich, M.W., Beckham, V., Wittenberg, C., et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 333:18 (1995), 1190–1195.
14. 14 Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Engl J Med 325:5 (1991), 293–302.
15. 15 Cohn, J.N., Tognoni, G., Valsartan Heart Failure Trial Investigators, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:23 (2001), 1667–1675.
16. 16 Granger, C.B., McMurray, J.J., Yusuf, S., et al., CHARM Investigators and Committees, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 362:9386 (2003), 772–776.
17. 17 Packer, M., Coats, A.J., Fowler, M.B., et al., Carvedilol Prospective Randomized Cumulative Survival Study Group, Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:22 (2001), 1651–1658.
18. 18 The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9146 (1999), 9–13.
19. 19 Pitt, B., Zannad, F., Remme, W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study investigators. N Engl J Med 341:10 (1999), 709–717.
20. 20 Pitt, B., Remme, W., Zannad, F., et al., Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. [Erratum appears in N Engl J Med. 2003;348(22):2271] N Engl J Med 348:14 (2003), 1309–1321.
21. 21 Digitalis Investigation Group, The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:8 (1997), 525–533.
22. 22 Pitt, B., Pfeffer, M.A., Assmann, S.F., et al., TOPCAT Investigators, Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:15 (2014), 1383–1392.
23. 23 Pfeffer, M.A., Claggett, B., Assmann, S.F., et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131:1 (2015), 34–42.
24. 24 Bristow, M.R., Saxon, L.A., Boehmer, J., et al., Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators, Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:21 (2004), 2140–2150.
25. 25 Cleland, J.G., Daubert, J.C., Erdmann, E., et al., Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators, The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:15 (2005), 1539–1549.
26. 26 Feldman, A.M., de Lissovoy, G., Bristow, M.R., et al. Cost effectiveness of cardiac resynchronization therapy in the comparison of medical therapy, pacing, and defibrillation in heart failure (COMPANION) trial. J Am Coll Cardiol 46:12 (2005), 2311–2321.
27. 27 Peterson, P.N., Greiner, M.A., Qualls, L.G., et al. QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy. JAMA 310:6 (2013), 617–626.
28. 28 Coats, A.J., Adamopoulos, S., Radaelli, A., et al. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function. Circulation 85:6 (1992), 2119–2131.
29. 29 Hambrecht, R., Niebauer, J., Fiehn, E., et al. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. J Am Coll Cardiol 25:6 (1995), 1239–1249.
30. 30 Belardinelli, R., Georgiou, D., Cianci, G., et al. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation 99:9 (1999), 1173–1182.
31. 31 Piepoli, M.F., Davos, C., Francis, D.P., et al., ExTraMATCH Collaborative, Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ, 328(7433), 2004, 189.
32. 32 O'Connor, C.M., Whellan, D.J., Lee, K.L., et al., HF-ACTION Investigators, Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301:14 (2009), 1439–1450.
33. 33 Georgiou, D., Chen, Y., Appadoo, S., et al. Cost-effectiveness analysis of long-term moderate exercise training in chronic heart failure. Am J Cardiol 87:8 (2001), 984–988.
34. 34 World Health Organization's definition of palliative care. Available at: http://www.who.int/cancer/palliative/definition/en/. Accessed January 11, 2015.
35. 35 Mozaffarian, D., Benjamin, E.J., Go, A.S., et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Executive summary: heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131:4 (2015), 434–441.
36. 36 Adler, E.D., Goldfinger, J.Z., Kalman, J., et al. Palliative care in the treatment of advanced heart failure. Circulation 120:25 (2009), 2597–2606.
37. 37 Morrison, R.S., Penrod, J.D., Cassel, J.B., et al., Palliative Care Leadership Centers' Outcomes Group, Cost savings associated with US hospital palliative care consultation programs. Arch Intern Med 168:16 (2008), 1783–1790.
38. 38 Collins, S.P., Pang, P.S., Lindsell, C.J., et al. International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. Eur J Heart Fail 12:11 (2010), 1253–1260.
39. 39 Adams, K.F. Jr., Fonarow, G.C., Emerman, C.L., et al., ADHERE Scientific Advisory Committee and Investigators, Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149:2 (2005), 209–216.
40. 40 Weintraub, N.L., Collins, S.P., Pang, P.S., et al., American Heart Association Council on Clinical Cardiology and Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation 122:19 (2010), 1975–1996.
41. 41 Rame, J.E., Sheffield, M.A., Dries, D.L., et al. Outcomes after emergency department discharge with a primary diagnosis of heart failure. Am Heart J 142:4 (2001), 714–719.
42. 42 Collins, S.P., Pang, P.S., Fonarow, G.C., et al. Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization. J Am Coll Cardiol 61:2 (2013), 121–126.
43. 43 Storrow, A.B., Collins, S.P., Lyons, M.S., et al. Emergency department observation of heart failure: preliminary analysis of safety and cost. Congest Heart Fail 11:2 (2005), 68–72.
44. 44 Ryder, M., Murphy, N.F., McCaffrey, D., et al. Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure. Eur J Heart Fail 10:3 (2008), 267–272.
45. 45 Lazkani, M., Ota, K.S., The role of outpatient intravenous diuretic therapy in a transitional care program for patients with heart failure: a case series. J Clin Med Res 4:6 (2012), 434–438.
46. 46 Adamson, P.B., Magalski, A., Braunschweig, F., et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol 41:4 (2003), 565–571.
47. 47 Bourge, R.C., Abraham, W.T., Adamson, P.B., et al., COMPASS-HF Study Group, Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol 51:11 (2008), 1073–1079.
48. 48 Ritzema, J., Troughton, R., Melton, I., et al., Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients (HOMEOSTASIS) Study Group, Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation 121:9 (2010), 1086–1095.
49. 49 Catanzariti, D., Lunati, M., Landolina, M., et al., Italian Clinical Service Optivol-CRT Group, Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure. Pacing Clin Electrophysiol 32:3 (2009), 363–370.
50. 50 Whellan, D.J., Ousdigian, K.T., Al-Khatib, S.M., et al., PARTNERS Study Investigators, Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study. J Am Coll Cardiol 55:17 (2010), 1803–1810.
51. 51 Abraham, W.T., Adamson, P.B., Bourge, R.C., et al., CHAMPION Trial Study Group, Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377:9766 (2011), 658–666.
52. 52 Keenan, P.S., Normand, S.L., Lin, Z., et al. An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. Circ Cardiovasc Qual Outcomes 1:1 (2008), 29–37.